PsiOxus Therapeutics’ adenovirus product in combination with Opdivo (nivo-lumab) for late-stage cancers.
Bristol-Myers Squibb (BMY) and PsiOxus Therapeutics (PsiOxus) announced an agreement to evaluate PsiOxus’ drug enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s checkpoint inhibitor opdivo (nivolumab) for a range of tumor types in late-stage cancer patients.
Enadenotucirev is designed to have immune stimulating effects while Opdivo is designed to alleviate immune suppression by the checkpoint protein PD-1. The collaboration aims at determining whether . . .
This content is for paid subscribers.
Today’s Highlights July 5, 2016